申请人:State of Oregon, acting by and through The Oregon State Board of Higher
公开号:US05620978A1
公开(公告)日:1997-04-15
Disclosed is a method of treating or preventing neuronal loss associated with stroke, ischemia, CNS trauma or hypoglycemia. The method comprises administering to an animal a compound of the formula: ##STR1## or a pharmaceutically acceptable salt thereof; wherein n is zero or 1; R.sup.4, R.sup.5, R.sup.6 are independently hydrogen, nitro, amino, halo, haloalkyl, cyano, alkyl, cycloalkyl, alkenyl, alkynyl, azido, acylamino, alkylsulfonyl, aryl, substituted aryl, heteroaryl, alkoxy, trialkylsilyl-substituted alkoxy, aryloxy, substituted aryloxy, heteroaryloxy, a heterocyclic group, a heterocyclicoxy group, aralkoxy, or haloalkoxy; and R.sup.c and R.sup.d are defined in the specification. These compounds have high binding to the glycine site of the NMDA receptor.
本发明揭示了一种用于治疗或预防与中风、缺血、中枢神经系统创伤或低血糖相关的神经元丢失的方法。该方法包括向动物投与以下化合物或其药学上可接受的盐:##STR1## 其中n为零或1;R.sup.4,R.sup.5,R.sup.6独立地为氢、硝基、氨基、卤素、卤基、氰基、烷基、环烷基、烯基、炔基、叠氮基、酰基氨基、烷基磺酰基、芳基、取代芳基、杂芳基、烷氧基、三烷基硅基取代的烷氧基、芳氧基、取代芳氧基、杂芳氧基、杂环基、杂环氧基、芳基烷氧基或卤基烷氧基;R.sup.c和R.sup.d在规范中有定义。这些化合物具有高度结合到NMDA受体的甘氨酸位点。